Texas Tech University Health Sciences Center, Department of Psychiatry, Amarillo, TX, USA; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
J Psychosom Res. 2019 Jun;121:68-73. doi: 10.1016/j.jpsychores.2019.04.004. Epub 2019 Apr 12.
Cannabis is the most commonly used non-alcohol intoxicant in the general population. There are no consistent guidelines on the implications of cannabis abuse and dependence (CAD) in kidney transplant candidates. The aims of this study were to characterize kidney transplant candidates with comorbid CAD and examine the implications of CAD on transplant candidacy.
This was a retrospective cohort study of kidney transplant candidates meeting diagnostic criteria for CAD at a tertiary center from 2012 to 2016. Candidates were reviewed for psychiatric and substance use disorders (SUDs), family history, and medical variables. The cohort was divided by severity of CAD and transplant listing status for comparisons. Statistical analysis included Kruskal-Wallis tests for continuous variables and Fisher's Exact Test for categorical variables.
Sixty-one of 2067 (3%) kidney transplant candidates met criteria for CAD, and 13/61 (21%) underwent transplantation. Of 61, 58% smoked cannabis daily, 47% had alcohol dependence history, 31% had other illicit drug dependencies, 38% were smokers, 60% had a SUD family history, and 42% and 27% had depressive and anxiety disorders, respectively. Severity of CAD was inversely associated with transplant listing; those with cannabis abuse were more often listed than those with dependence (67% vs 33%, p = .02) by study end. Three case presentations illustrate cannabis-related issues.
In this cohort, kidney transplant candidates with comorbid CAD have high prevalence of other substance use disorders, psychiatric comorbidities, and strong family histories of addictions that resemble other SUD populations. These findings have implications for pre-transplant screening and treatment and post-transplant monitoring.
大麻是普通人群中最常使用的非酒精致醉物质。目前,尚无关于大麻滥用和依赖(CAD)对肾移植候选者影响的一致性指南。本研究的目的是描述合并 CAD 的肾移植候选者的特征,并研究 CAD 对候选者移植资格的影响。
这是一项回顾性队列研究,研究对象为 2012 年至 2016 年在一家三级中心符合 CAD 诊断标准的肾移植候选者。对候选者进行了精神病和物质使用障碍(SUD)、家族史和医学变量的评估。根据 CAD 的严重程度和移植名单状态对队列进行了分组,以进行比较。统计分析包括连续变量的 Kruskal-Wallis 检验和分类变量的 Fisher 精确检验。
在 2067 名肾移植候选者中,有 61 名(3%)符合 CAD 标准,其中 13 名(21%)接受了移植。在这 61 名患者中,58%的人每天吸食大麻,47%的人有酒精依赖史,31%的人有其他非法药物依赖,38%的人吸烟,60%的人有 SUD 家族史,分别有 42%和 27%的人患有抑郁障碍和焦虑障碍。CAD 的严重程度与移植名单呈负相关;研究结束时,滥用大麻的患者比依赖大麻的患者更常被列入名单(67%比 33%,p=0.02)。三个病例介绍说明了与大麻相关的问题。
在本队列中,合并 CAD 的肾移植候选者具有较高的其他物质使用障碍、精神共病和强烈的成瘾家族史,这与其他 SUD 人群相似。这些发现对移植前筛查和治疗以及移植后监测具有重要意义。